Publications by authors named "A Pingle"
Article Synopsis
- Tafenoquine, a single 300 mg dose combined with a 3-day chloroquine treatment, is approved for curing Plasmodium vivax malaria in patients 16 and older, offering a more convenient alternative to the traditional multi-day regimens with primaquine.
- * The World Health Organization (WHO) recommends longer primaquine treatments which can lead to poor adherence, whereas tafenoquine's single-dose approach enhances patient compliance.
- * Safety studies indicate that tafenoquine has a similar safety profile to primaquine, but both can cause serious complications in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, so G6PD testing is essential before treatment.*
A single 300 mg dose of tafenoquine, in combination with chloroquine, is currently approved in several countries for the radical cure (prevention of relapse) of malaria in patients aged ≥16 years. Recently, however, Watson et al. suggested that the approved dose of tafenoquine is insufficient for radical cure, and that a higher 450 mg dose could reduce P.
View Article and Find Full Text PDFOpioids are an indispensable part of perioperative pain management of cancer surgeries. Opioids do have some side effects and abuse potential, and some laboratory data suggest a possible association of cancer recurrence with perioperative opioid use. Opioid-free anesthesia and opioid-sparing anesthesia are emerging new concepts worldwide to safeguard patients from adverse effects of opioids and potential abuse.
View Article and Find Full Text PDFCoronavirus disease 2019 (COVID-19) has gripped the world and is evolving day by day with deaths every hour. Being immunocompromised, cancer patients are more susceptible to contract the infection. Onco-surgeries on such immunocompromised patients have an increased risk of infection of COVID-19 to patients and health care workers.
View Article and Find Full Text PDF